Director/PDMR Shareholding & Total Voting Rights

Proteome Sciences plc

(the "Company")

Director/PDMR Shareholding & Total Voting Rights

 

Proteome Sciences plc (AIM:PRM) announces that further to the announcement on 31 October 2016 regarding a placing (the "Placing") to raise £3.3 million, the first tranche of 45,593,346 ( new ordinary shares of 1 pence each in the capital of the Company ("Ordinary Shares") have today been admitted to trading on AIM ("Admission").

 

Jeremy Haigh, Chief Executive Officer of the Company, and Roger McDowell, Non-Executive Director of the Company, both participated in the Placing. The number of Placing Shares purchased by the Directors and their beneficial interest in the capital of the Company is set out below:

 

	No. of new Ordinary Shares purchased	Resultant number of Ordinary Shares following the Placing	Interest in total issued share capital following the Placing
Jeremy Haigh	400,000	400,000	0.15%
Roger McDowell	2,000,000	2,500,000	0.91%

 

Following Admission, the Company's issued share capital is 273,660,078 Ordinary Shares. The above figure of 273,660,078 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure and Transparency Rules.

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 

1.	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Jeremy Haigh
2.	Reason for the Notification
a)	Position/status	Chief Executive Officer
b)	Initial notification/Amendment	Initial notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Proteome Sciences plc
b)	LEI	n/a
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the Financial instrument, type of instrument	Ordinary Shares of 1p each
	Identification code	GB0003104196
b)	Nature of the transaction	Subscription to purchase Ordinary Shares
c)	Price(s) and volume(s)	Price(s) Volume(s) 5p 400,000
d)	Aggregated information: ·      Aggregated volume ·      Price	400,000  Ordinary Shares of 1 pence each purchased at 5 pence per Ordinary Share
e)	Date of the transaction	4 November 2016
f)	Place of the transaction	London Stock Exchange, AIM Market (XLON)

 

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 

1.	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Roger McDowell
2.	Reason for the Notification
a)	Position/status	Non-Executive Director
b)	Initial notification/Amendment	Initial notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Proteome Sciences plc
b)	LEI	n/a
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the Financial instrument, type of instrument	Ordinary Shares of 1p each
	Identification code	GB0003104196
b)	Nature of the transaction	Purchase of Ordinary Shares
c)	Price(s) and volume(s)	Price(s) Volume(s) 5p 2,000,000
d)	Aggregated information: ·      Aggregated volume ·      Price	2,000,000  Ordinary Shares of 1 pence each purchased at 5 pence per Ordinary Share
e)	Date of the transaction	4 November 2016
f)	Place of the transaction	London Stock Exchange, AIM Market (XLON)